UK's Recovery trial to continue testing Roche drug for Covid-19
Coronavirus chronicle
29 July, 2020, 03:30 pm
Last modified: 29 July, 2020, 03:34 pm
"We will be continuing with the arm of the RECOVERY trial for the moment," a spokeswoman for the RECOVERY team said
FILE PHOTO: The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland January 30, 2020. REUTERS/Arnd Wiegmann/File Photo
A major UK trial looking at whether some existing drugs may be used to treat Covid-19 is to continue testing Roche's arthritis drug Actemra, also known as tocilizumab, despite separate trial results on Wednesday showing it had no benefit.
"We will be continuing with the arm of the RECOVERY trial for the moment," a spokeswoman for the RECOVERY team told Reuters.
"We are investigating the use of tocilizumab for sicker patients, whereas the Roche trial looked at patients with milder disease," she added.
Data from Roche earlier on Wednesday showed that a trial of Actemra/RoActemra drug to treat patients hospitalised with Covid-19-related pneumonia had failed.
Comments
While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.